tm logo
CONNECTD
Live/Pending
PUBLISHED FOR OPPOSITION

on 30 Apr 2024

Last Applicant/ Owned by

400 Interpace Parkway

Parsippany

NJ

07054

Serial Number

98135426 filed on 16th Aug 2023

Registration Number

N/A

Correspondent Address

Laurence Rickles TEVA PHARMACEUTICALS USA, INC.

400 INTERPACE PARKWAY

BUILDING A

PARSIPPANY, NJ 07054

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

CONNECTD

Medical services, namely, providing information relating to tardive dyskinesia to medical and health care professionals The color(s) Black, blue and purple is/are claimed as a feature of the mark. CONNECTED; CONNECT TD The mark consists of the stylized wording "connecTD" with the letters "connec" in small black text, the letter "T" in large blue text and the letter "D" offset and in large purplRead More

Classification Information


Class [044]
Medical, Beauty & Agricultural Services


Medical services, namely, providing information relating to tardive dyskinesia to medical and health care professionals


First Use Date in General

11th 000101

First Use Date in Commerce

11th 000101

Mark Details


Serial Number

No 98135426

Mark Type

No Service Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Description of Design Search

The mark consists of the stylized wording "connecTD" with the letters "connec" in small black text, the letter "T" in large blue text and the letter "D" offset and in large purple text.

Legal History


Show more

Status DateAction Taken
30th Apr 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30th Apr 2024PUBLISHED FOR OPPOSITION
10th Apr 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
25th Mar 2024APPROVED FOR PUB - PRINCIPAL REGISTER
20th Mar 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
20th Mar 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
20th Mar 2024TEAS/EMAIL CORRESPONDENCE ENTERED
15th Mar 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
15th Mar 2024NON-FINAL ACTION E-MAILED
15th Mar 2024NON-FINAL ACTION WRITTEN